» Articles » PMID: 38948451

Antifungal Activity of 3-Hydrazinoquinoxaline-2-Thiol, a Novel Quinoxaline Derivative Against Candida Species

Overview
Journal Mycobiology
Date 2024 Jul 1
PMID 38948451
Authors
Affiliations
Soon will be listed here.
Abstract

ranks as among the most frequently encountered fungal infections that associated with high morbidity and mortality. Quinoxaline derivatives are a group of small molecules that showed a promising antimicrobial activity. This study aimed to investigate the fungicidal effects of 3-hydrazinoquinoxaline-2-thiol against in comparison with Amphotericin B as a reference. Also, we aim to assess the efficacy of 3-hydrazinoquinoxaline-2-thiol using mice oral candidiasis model. Fifty-six isolates were subjected to susceptibility testing by broth microdilution method for 3-hydrazinoquinoxaline-2-thiol and Amphotericin B. Therefore, Minimal inhibitory concentrations (MIC) were assessed and compared. The oral candidiasis mice model was used to evaluate the activity of 3-hydrazinoquinoxaline-2-thiol . Microbiological evaluation of progression and ELISA were used in this study. 3-hydrazinoquinoxaline-2-thiol was more effective than Amphotericin B against most clinical isolates of . Higher effectiveness was seen against and isolates. However, the efficiency against isolates varies. 3-hydrazinoquinoxaline-2-thiol was also effective against and . 3-hydrazinoquinoxaline-2-thiol showed a good efficacy in mice model against cells ATCC 10231. 3-hydrazinoquinoxaline-2-thiol has shown promising antifungal and anti-inflammatory activity against different species. More tests and experiments are needed.

References
1.
Ashburn T, Thor K . Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004; 3(8):673-83. DOI: 10.1038/nrd1468. View

2.
Patil S, Rao R, Majumdar B, Anil S . Clinical Appearance of Oral Candida Infection and Therapeutic Strategies. Front Microbiol. 2016; 6:1391. PMC: 4681845. DOI: 10.3389/fmicb.2015.01391. View

3.
Jose P, Alvarez-Lerma F, Maseda E, Olaechea P, Peman J, Soriano C . Invasive fungal infection in crtically ill patients: hurdles and next challenges. J Chemother. 2019; 31(2):64-73. DOI: 10.1080/1120009X.2018.1557799. View

4.
Groll A, Townsend R, Desai A, Azie N, Jones M, Engelhardt M . Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4. Transpl Infect Dis. 2017; 19(5). DOI: 10.1111/tid.12751. View

5.
Barchiesi F, Orsetti E, Osimani P, Catassi C, Santelli F, Manso E . Factors related to outcome of bloodstream infections due to Candida parapsilosis complex. BMC Infect Dis. 2016; 16:387. PMC: 4977692. DOI: 10.1186/s12879-016-1704-y. View